본문 바로가기

Differential Effects of 1 alpha,25-Dihydroxyvitamin D-3 on the Expressions and Functions of Hepatic CYP and UGT Enzymes and Its Pharmacokinetic Consequences In Vivo

Differential effects of 1α,25-dihydroxyvitamin D3 on the expressions and functions of hepatic CYP and UGT enzymes and its pharmacokinetic consequences in vivo

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q2
저널
PHARMACEUTICS12(11) · pp.1 · 2020
피인용
Web of Science 17Scopus 17
FWCI (Scopus)
0
JCR IF
JCR 2019 4.421
ISSN
1999-4923

저자

  1. Doan, Trang Nguyen Kieu제1저자Department of Pharmacy, College of Pharmacy, Gachon University, Incheon, 21936, Korea;
  2. Vo, Dang-KhoaDepartment of Pharmacy, College of Pharmacy, Gachon University, Incheon, 21936, Korea;
  3. Kim, HyojungDepartment of Pharmacology, Sungkyunkwan University School of Medicine, Suwon, 16419, Korea;
  4. Balla, AnushaDepartment of Pharmacy, College of Pharmacy, Gachon University, Incheon, 21936, Korea;
  5. Lee, YunjongDepartment of Pharmacology, Sungkyunkwan University School of Medicine, Suwon, 16419, Korea;
  6. 윤인수교신저자Department of Manufacturing Pharmacy, College of Pharmacy, Pusan National University, Busan, 46241, Korea
  7. Maeng, Han-Joo교신저자Department of Pharmacy, College of Pharmacy, Gachon University, Incheon, 21936, Korea;

초록

The compound 1 alpha,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) is the active form of vitamin D-3 and a representative ligand of the vitamin D receptor (VDR). Previous studies have described the impacts of 1,25(OH)(2)D-3 on a small number of cytochrome P450 (CYP) and uridine diphosphate-glucuronyltransferase (UGT) enzymes, but comparatively little is known about interactions between several important CYP and UGT isoforms and 1,25(OH)(2)D-3 in vitro and/or in vivo. Thus, we investigated the effects of 1,25(OH)(2)D-3 on the gene and protein expressions and functional activities of selected CYPs and UGTs and their impacts on drug pharmacokinetics in rats. The mRNA/protein expressions of Cyp2b1 and Cyp2c11 were downregulated in rat liver by 1,25(OH)(2)D-3. Consistently, the in vitro metabolic kinetics (V-max and CLint) of BUP (bupropion; a Cyp2b1 substrate) and TOL (tolbutamide; a Cyp2c11 substrate) were significantly changed by 1,25(OH)(2)D-3 treatment in liver microsomes, but the kinetics of acetaminophen (an Ugt1a6/1a7/1a8 substrate) remained unaffected, consistent with Western blotting data for Ugt1a6. In rat pharmacokinetic studies, the total body clearance (CL) and nonrenal clearance (CLNR) of BUP were significantly reduced by 1,25(OH)(2)D-3, but unexpectedly, the total area under the plasma concentration versus time curve from time zero to infinity (AUC) of hydroxybupropion (HBUP) was increased probably due to a marked reduction in the renal clearance (CLR) of HBUP. Additionally, the AUC, CL, and CLNR for TOL and the AUC for 4-hydroxytolbutamide (HTOL) were unaffected by 1,25(OH)(2)D-3 in vivo. Discrepancies between observed in vitro metabolic activity and in vivo pharmacokinetics of TOL were possibly due to a greater apparent distribution volume at the steady-state (V-ss) and lower plasma protein binding in 1,25(OH)(2)D-3-treated rats. Our results suggest possible drug-drug and drug-nutrient interactions and provide additional information concerning safe drug combinations and dosing regimens for patients taking VDR ligand drugs including 1,25(OH)(2)D-3.

키워드

CYPUGT125(OH)(2)D-3pharmacokineticsmetabolic kineticsvitamin D receptordrug-drug interactionsVITAMIN-D-RECEPTORADEFOVIR DIPIVOXILLIVERRATDISPOSITIONTOLBUTAMIDECALCITRIOLBUPROPIONSUPPLEMENTATIONCYTOCHROME-P4501,25(OH)2D3

식별자

Scopus EID
2-s2.0-85096454582
WoS UID
000593912600001